U.S. Oncology Plans To Go Private Ahead Of Medicare Rx, But Seeking Other Bidders
This article was originally published in The Pink Sheet Daily
The cancer care services company has worked out a $1.7 bil. buyout deal, but can actively solicit other offers until April 16. By going private, U.S. Oncology avoids wide fluctuations in its share price and possible future cuts in reimbursement.
You may also be interested in...
The company has signed an agreement to sell its Oncology Therapeutics Network to One Equity Partners, Bristol announces. The transaction is expected to close during the first quarter of 2005.
Surge of interest prompts US FDA to consider how to adjust feedback, including potentially creating a separate team to answer more basic questions.